Therapeutic treatment of upper respiratory infections using a nasal spray
View Patent ↗A method for treating a streptococcal infection is disclosed using a nasal spray. The spray comprises an effective amount of a lysin enzyme genetically coded for by a C1 bacteriophage capable of infecting a group C Streptococcal bacteria, and a nasal spray carrier for delivering said lysin enzyme to a mouth, throat, or nasal passage.
1. A method for treating a Streptococcus Group A infection, comprising:
administering a nasal spray to a potentially infected nose, said nasal spray comprising:
(i) an effective amount of a lysin enzyme genetically coded for by a C1 bacteriophage capable of infecting a group C Streptococcal bacteria , said lysin enzyme characterized by the ability to destroy the cell wall of said Streptococcus Group A bacteria; and
(ii) a nasal spray carrier for delivering said lysin enzyme to a nasal passage.
2. The method according to claim 1 , further comprising a buffer that maintains pH of the nasal spray at a range between about 4.0 and 9.0.
3. The method according to claim 2 , wherein said buffer maintains the pH of the nasal spray at range between 5.5 and 7.5.
4. The method according to claim 2 , wherein said buffer comprises a reducing agent.
5. The method according to claim 4 , wherein said reducing agent is dithiothreitol.
6. The method according to claim 2 , wherein said buffer comprises a metal chelating agent.
7. The method according to claim 2 , wherein said buffer is a citrate-phosphate buffer.
8. The method according to claim 5 , further comprising a bactericidal or bacteriostatic agent as a preservative.